Glafenine

CAS No. 3820-67-5

Glafenine( Glafenine | Glafenin | Glafenina )

Catalog No. M14324 CAS No. 3820-67-5

Glafenine is a non-steroidal anti-inflammatory drug (NSAID), is a non-narcotic analgesic agent, widely used for the treatment of pains of various origins..

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 32 In Stock
100MG 45 In Stock
200MG 61 In Stock
500MG 133 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Glafenine
  • Note
    Research use only, not for human use.
  • Brief Description
    Glafenine is a non-steroidal anti-inflammatory drug (NSAID), is a non-narcotic analgesic agent, widely used for the treatment of pains of various origins..
  • Description
    Glafenine is a non-steroidal anti-inflammatory drug (NSAID), is a non-narcotic analgesic agent, widely used for the treatment of pains of various origins.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Glafenine | Glafenin | Glafenina
  • Pathway
    Chromatin/Epigenetic
  • Target
    COX
  • Recptor
    COX
  • Research Area
    Inflammation/Immunology
  • Indication
    ——

Chemical Information

  • CAS Number
    3820-67-5
  • Formula Weight
    372.8
  • Molecular Formula
    C19H17ClN2O4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    O=C(OCC(O)CO)C1=CC=CC=C1NC2=CC=NC3=CC(Cl)=CC=C23
  • Chemical Name
    2,3-Dihydroxypropyl N-(7-chloro-4-quinolyl) anthranilate

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kleinknecht D, et al. Clin Nephrol. 1986 Jun;25(6):275-8
molnova catalog
related products
  • Firocoxib

    Firocoxib is a selective non-steroidal inhibitor of cycooxygenase-2 (COX-2) (IC50 of 0.13 μM), with anti-inflammatory for use in dogs and horses.

  • 8-SHOGAOL

    8-?Shogaol is a component of ginger and maintains anti-inflammatory activity as a cyclooxygenase-2 inhibitor.

  • Valdecoxib

    Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about possible increased risk of heart attack and stroke.